The latest medical insurance reimbursement price of Jisandai (Bingtonsha) hepatitis C drug in 2024

Epclusa is a drug specially used to treat chronic hepatitis C. This type of hepatitis is caused by the hepatitis C virus (HCV). If not treated in time, it may gradually evolve into serious diseases such as cirrhosis and even liver cancer.

Today, Jisandai (Bingtonsha) has officially debuted in the domestic market and is covered by the medical insurance system. Patients can easily purchase this drug in China, and the price remains at about two to three thousand yuan. However, regarding the specific costs of drugs and the details of medical insurance reimbursement, it is still recommended that you go to your local hospital or pharmacy for specific consultation. If you're looking for a more cost-effective option, the generic version of Bingtonsa may be a good choice. Especially the Bangladeshi and Indian versions of generic drugs are relatively affordable, ranging from a few hundred to more than a thousand yuan, and their pharmaceutical ingredients are highly similar to domestic original drugs.

Gilead is an oral drug developed by Gilead Sciences in the United States. It is a type of direct antiviral drug (DAAs) that treats hepatitis C by inhibiting the replication of the virus. It is actually a compound medicine containing two key ingredients: sofosbuvir (sofosbuvir) and velbipravir (velpatasvir). Sofosbuvir acts as a nucleoside reverse transcriptase inhibitor, while vilbipravir acts as an NS5A inhibitor. The combination of the two makes Bingtonsa have a broad inhibitory effect on the hepatitis C virus and can attack different targets of the virus at the same time, thereby improving the therapeutic effect.

The treatment plan for Jisandai (Bingtonsha) is relatively simple. It is usually recommended that patients take one pill every day and continue treatment for about 12 weeks. Compared with traditional interferon and ribavirin treatment options, Gsanda not only has a higher cure rate, but also has fewer side effects. Its efficacy has been fully verified in clinical trials and has been confirmed to have good effects on a variety of hepatitis C virus genotypes.

When patients use Jisandai (Bingtonsha) to treat chronic hepatitis C, they should strictly follow the doctor's instructions and undergo regular examinations to evaluate the treatment effect and possible side effects. Although Jisandai (Bingtonsha) is considered a safe and effective drug, some adverse reactions such as headache, fatigue, nausea, diarrhea, etc. may still occur during use. Therefore, patients need to always pay attention to their physical condition and promptly report any abnormal reactions to their doctors.